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Abstract 
In this study, authors  developed a simple, sensitive and specific liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) method for 
quantification of Amisulpride in human plasma using Amisulpride-d5  as an 
internal standard (IS). Chromatographic separation was performed on Zorbax 
Bonus-RP C18, 4.6 x 75 mm, 3.5 µm column with an isocratic mobile phase 
composed of 0.2% formic acid:methanol (35:65 v/v), at a flow-rate of 
0.5 mL/min. Amisulpride, Amisulpride-d5 was detected at m/z 370.1→242.1 and 
375.1→242.1. The drug and the IS were extracted by a liquid-liquid extraction 
method. The method was validated over a linear concentration range of   
2.0–2500.0 ng/mL for Amisulpride with a correlation coefficient of (r
2) ≥ 0.9982. 
This method demonstrated intra- and inter-day precision within 0.9 to 1.7 and 
1.5 to 2.8 % and intra- and inter-day accuracy within 98.3 to 101.5 and 96.0 to 
101.0 % for Amisulpride. Amisulpride was found to be stable at 3 freeze–thaw 
cycles, bench top and auto sampler stability studies. The developed method 
was successfully applied to a pharmacokinetic study. 584  R. Mogili et al.:   
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Introduction 
Amisulpride,  4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenz-
amide, has a molecular formula of C17H27N3O4S and a molecular weight of 369.48 g/mol 
(Fig.1) [1].  Amisulpride  is an ortho-methoxybenzamide derivative chemically related to 
sulpiride. This CNS agent shows a high affinity for dopamine D2 and D3 receptors and 
demonstrates anti schizophrenic and antidysthymic (antidepressant) properties [2, 3]. This 
drug is effective as maintenance therapy in patients with chronic schizophrenia,  and 
generally a long-term treatment with Amisulpride was associated with improvement in 
quality of life and social functioning [4]. Amisulpride is generally well tolerated and the 
neurological tolerability  profile is superior to that of conventional antipsychotics (e.g. 
haloperidol and flupenthixol) [5, 6].  Amisulpride poisoning may induce seizures, QT 
prolongation and torsades de pointes [7].  
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Fig. 1.  Chemical structures of Amisulpride and Amisulpride-d5 
After a single oral dose of 50 mg racemic Amisulpride, the drug shows a rapid absorption 
with an absolute bioavailability of about 50% and a biphasic absorption profile [8–10]. After 
a 50 mg oral dose, the renal clearance ranges from about 17–20 l/h and exhibits little 
variation with the dose administered but correlates linearly with creatinine clearance (the 
plasma systemic clearance is about 31–421/h) [8–11].  
Literature survey reveals that for quantification of amisulpride in biological samples by LC-
MS/MS  [12–18], HPLC [19–36],  pharmaceuticals by chromatographic, electrophoretic, 
spectrophotometric [37] and voltametric [38] were reported. Of all of the studies, Nirogi et 
al. [12] achieved better results for quantitative estimation of amisulpride in human plasma. 
Authors could not achieve better results for quantification of amisulpride in terms of 
sensitivity, runtime, consumption of mobile phase and in recovery. 
The aim of the present research is to develop and validate a simple, sensitive, selective, 
fast, rugged and reproducible analytical method for quantification of Amisulpride in Human 
plasma samples by liquid chromatography coupled to electro spray (ES) tandem mass 
spectrometry. Moreover, the analyte is compared  with  a  deuterated internal standard, 
which is most useful in selectivity and matrix effect experiments using LC-MS/MS. 
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Material and methods 
Standards and chemicals 
Amisulpride and Amisulpride-d5 were obtained from Toronto Research Chemicals Canada. 
Human plasma (K2EDTA) was obtained from Navjeevan Blood Bank, Hyderabad. Formic 
acid,  diethyl ether, methanol  and  acetone  were purchased from SD-Fine  Chemicals, 
Mumbai. Ultra-pure water was obtained from a Milli-Q System. 
Instrumentation  
HPLC system (1200 series model, Agilent Technologies, Waldbronn, Germany), Mass 
spectrometry API 4000 triple quadrupole instrument (ABI-SCIEX, Toronto, Canada) using 
MRM.  
Detection 
Turbo ionspray (API) positive mode with Unit Resolution, MRM was used for the detection 
of Amisulpride and Amisulpride-d5. The [MH]
+  was monitored at  m/z:  370.1, for 
Amisulpride and m/z: 375.2 for Amisulpride-d5. Fragments of m/z: 242.0 for Amisulpride 
and m/z: 242.1 Amisulpride-d5  formed from the respective precursor ions. Mass 
parameters were optimized as source temperature 500 °C, nebulizer source gas 30 
(nitrogen) psi, heater gas 45  (nitrogen) psi,  curtain gas 20  (nitrogen) psi, CAD gas 7 
(nitrogen) psi, Ion Spray (IS) voltage 5500 volts, source flow rate 500 µL/min without split, 
entrance potential 10 V, collision cell exit potential (CXP) 12 V, declustering potential (DP) 
70 V, Collision energy 38 V for Amisulpride and Amisulpride-d5. 
Chromatographic conditions 
Zorbax Bonus-RP C18, 4.6 x 75 mm, 3.5 µm was selected as the analytical column at a 
temperature  of  30°C.  The mobile phase composition was 0.2% formic acid:  methanol 
(35:65 v/v) at a flow rate of 0.5 mL/min. Amisulpride-d5 was found to be an appropriate 
internal standard in  terms of chromatography and extractability. The retention time of 
Amisulpride, Amisulpride-d5 was found to be approximately 1.1 ± 0.2 min. 
Preparation of standards and quality control (QC) Samples 
Standard stock solutions of Amisulpride (250.00 µg/mL) and Amisulpride-d5 (250.00µg/mL) 
were prepared in methanol. The spiking solution for Amisulpride-d5 was prepared in 50% 
methanol from the respective standard stock solution. Standard stock solutions and IS 
spiking solutions were stored in refrigerator conditions (2–8°C) until analysis. Standard 
stock solutions  were added to drug-free human plasma to obtain Amisulpride 
concentration levels of 2.0, 4.0, 10.0, 25.0, 250.0, 500.0, 1000.0, 1500.0, 2000.0 and 
2500.0 ng/mL for analytical standards and 2.0, 6.0, 750.0 and 1750.0 ng/mL for quality 
control  standards and stored in a −30°C  set point freezer until analysis. The aqueous 
standards were prepared in reconstitution solution (0.2% formic acid: methanol (35:65 v/v) 
for validation exercises until analysis. 
Sample preparation 
Liquid-liquid extraction was used to isolate Amisulpride and Amisulpride-d5 from human 
plasma. 100 µL of IS (200.0 ng/mL) and 100 µL of plasma sample (respective 
concentration) were added respectively into ria-vials and vortexed briefly. Then, 2.5 mL of 586  R. Mogili et al.:   
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extraction solvent (diethyl ether) was added and vortexed for approximately 20 min. This 
was followed by centrifugation at 4000 rpm for 10 min at 20°C. Then samples were flash 
frozen  using dry-ice/acetone. The supernatant from each ria-vial was transferred into 
another set of ria-vials. These samples were evaporated at 40°C under nitrogen up to 
dryness. Finally, the dried residue samples were reconstituted with 500 µL of reconstitution 
solution and vortexed briefly. These samples were transferred into auto sampler vials and 
injected into LC-MS/MS. 
Method Development and Validation 
LC-MS/MS has been used as one of the most powerful analytical tools in clinical 
pharmacokinetics for its selectivity, sensitivity and reproducibility. The goal of this work is 
to develop and validate a simple, sensitive, rapid method for quantitative estimation of 
Amisulpride from plasma samples.  
Mass Spectrometry Optimization 
The MS optimization was  performed by direct infusion of both the solutions,  namely 
Amisulpride and Amisulpride-d5, into the mass spectrometer. The critical parameters in the 
ESI source include the needle voltage and temperature. 
Other parameters, such as the nebulizer and heater gases, DP, EP, CE, and CXP were 
optimized to obtain a better spray shape, resulting in better ionization of the protonated 
ionic Amisulpride and Amisulpride-d5. A CAD product ion spectrum of Amisulpride and 
Amisulpride-d5 formed with the fragment ions at m/z 242.1 for Amisulpride and m/z 242.1 
for Amisulpride-d5 (Fig. 2a–d). 
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Fig. 2b.  Mass spectrum of Amsulpride product ion 
 
 
Fig. 2c.   Mass spectrum of Amsulpride-d5 parent ion 588  R. Mogili et al.:   
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Fig. 2d.   Mass spectrum of Amsulpride-d5 product ion 
Chromatographic optimization 
Initially, we tried different extraction techniques such as SPE, Precipitation techniques. 
Finally, LLE was selected as a suitable extraction technique for the drug and IS in terms of 
recovery and reproducibility. Chromatographic conditions, especially the composition and 
nature of the mobile phase as well as the column, were optimized through several trials to 
achieve the best resolution to increase the signal of Amisulpride and Amisulpride-d5. A 
good separation and elution were achieved with 0.2% Formic acid: Methanol (35:65v/v) as 
the mobile phase, at a flow-rate of 0.5 mL/min and injection volume of 5 µL. 
The developed method is to be proved  by proper validation parameters (selectivity & 
specificity, linearity, precision & accuracy, recovery, LOQ&LOD, matrix effect and stability) 
as per standard regulatory guidelines. 
Selectivity & Specificity  
The selectivity of the method was determined by blank human plasma samples from six 
different lots to test the potential interference of endogenous compounds co-eluted with 
the drug  and  IS. The chromatographic peaks of Amisulpride and Amisulprid-d5  were 
identified based on their retention times and MRM responses. The mean peak area of 
LOQ for Amisulpride and Amisulprid-d5 at corresponding retention times in blank samples 
should not be more than 20 and 5% respectively.  
Linearity, precision and accuracy  
The analytical curves were constructed using values ranging from 2.0 to 2500.0 ng/mL for 
Amisulpride  in human plasma. Calibration curves were obtained by weighted 1/conc
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quadratic regression analysis. The ratio of Amisulpride peak area to Amisulpride-d5 peak 
area was plotted against the ratio of Amisulpride  concentration to Amisulpride-d5 
concentration in ng/mL. Calibration curve standard samples were prepared in each set and 
quality control samples were prepared in replicates (n=6) for analysis. The correlation 
coefficient >0.9850 was obtained for Amisulpride. Precision and accuracy for the back 
calculated concentrations of the calibration points, should be within ≤ 15 ± 15% of their 
nominal values. However, for LLOQ the precision and accuracy should be within ≤ 20 ± 
20%. 
Recovery 
The extraction recovery of Amisulpride and Amisulpride-d5  from human plasma was 
determined by analyzing quality control samples. Recovery at three concentrations (6.0, 
750.0 and 1750.0 ng/mL) was determined by comparing peak areas obtained from the 
plasma sample and the standard solution spiked with the blank plasma residue. A 
recovery of more than 50 % was considered adequate to obtain required sensitivity.  
Limits of Quantification (LOQ) & Detection (LOD) 
The response (peak area) was determined in blank plasma samples (six replicates from 
different plasma) and spiked LOQ sample prepared from the same plasma was 
determined. The peak area of blank samples should not be more than 20% of the mean 
peak area of LOQ of Amisulpride, and not more than 5% of Amisulpride. The precision and 
mean accuracy of the back calculated LOQ replicate concentrations must be ≤ 20 and ± 
20%, respectively.  
Matrix effect 
The matrix effect due to the plasma matrix was used to evaluate the ion 
suppression/enhancement in a signal when comparing the absolute response of QC 
samples after pretreatment (Liquid-liquid extraction) with the reconstitution samples 
extracted from blank plasma sample spiking with analyte. Experiments were performed at 
MQC levels in triplicate with six different plasma lots with the acceptable precision (%CV) 
of ≤ 15%. 
Stability (freeze–thaw, auto sampler, bench top, long term)  
Low quality control and high quality control samples (n=6) were retrieved from the deep 
freezer after three freeze-thaw cycles according to the clinical protocol. Samples were 
frozen at −30°C in three cycles of 24, 36 and 48 h. In addition, the long-term stability of 
Amisulpride in quality control samples was also evaluated by analysis after 80 days of 
storage at −30°C. Autosampler stability was studied following a 99 h storage period in the 
autosampler tray with control concentrations. Bench top stability was studied for a 25 h 
period with control concentrations. Stability samples were processed and extracted along 
with the freshly spiked calibration curve standards. The precision and accuracy for the 
stability  samples  must  be  within  ≤ 15 and ± 15 % respectively of their nominal 
concentrations. 
Analysis of human samples 
The bioanalytical method described above was used to determine Amisulpride 
concentrations in plasma following oral administration to healthy human volunteers. Each 590  R. Mogili et al.:   
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volunteer  gave  written informed consent before participating in this study. Ten healthy 
volunteers were chosen as subjects and orally administered a 50 mg dose (one 50 mg 
tablet) with 240 mL of drinking water. The reference  product, Solian tablets (Sanofi-
Aventis) 50 mg, and the test product, AM tablets (test tablet) 50 mg were used. Study 
protocol was approved by IEC (Institutional Ethical committee) as per ICMR (Indian 
Council of Medical Research). Blood samples were collected as pre-dose (0) h, 5 min prior 
to dosing followed by further samples at 0.25, 0.5, 0.75, 1.0, 1.333, 1.667, 2.0, 2.5, 3.0, 
3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0, 9.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 60 h. After dosing, 5 
mL of blood was collected each time in vaccutainers containing K2EDTA. A total of 48 (24 
time points for test and 24 time points for reference) time points were collected from each 
volunteer. The samples were centrifuged at 3200 rpm, 10°C, 10 min, and stored at −30°C 
until sample analysis. Test and reference tablets were administered to the same human 
volunteers under fasting conditions separately with proper washing periods (42 days gap 
between test and reference doses) as per protocol approved by IEC. 
Pharmacokinetics and statistical analysis 
Pharmacokinetic parameters from the human plasma samples were calculated by a 
noncompartmental statistics model using WinNon-Lin5.0 software (Pharsight, USA). Blood 
samples were taken for a period of 3 to 5 times the terminal elimination half-life (t1/2) and it 
was considered as the area under the concentration time curve (AUC) ratio higher than 
80% as per FDA guidelines [39–41]. Plasma AM concentration-time profiles were visually 
inspected and Cmax  and Tmax  values were determined. The AUC0–t  was obtained by 
trapezoidal method. AUC0-∞ was calculated up to the last measureable concentration and 
extrapolations were obtained using the last measureable concentration and the terminal 
elimination rate constant (Ke). The terminal elimination rate constant (Ke) was estimated 
from the slope of the terminal exponential phase of the plasma of AM concentration–time 
curve by means of linear regression. The terminal elimination half-life, t1/2, was then 
calculated as 0.693/Ke. Regarding AUC0–t  and Cmax  bioequivalence was assessed by 
means of analysis of variance (ANOVA) and calculating the standard 90% confidence 
intervals  (90% CIs) of the ratios test/reference (logarithmically-transformed data). The 
bioequivalence was considered when the ratio of averages of log-transformed data was 
within 80–125% for AUC0–t and Cmax. 
Results and Discussion 
Selectivity & Specificity 
The analysis of Amisulpride and Amisulpride-d5 using MRM function was highly selective 
with no interfering compounds. Fig. 3a  is  showing  plasma  only for one blank. 
Chromatograms obtained from plasma (LOQ) spiked with Amisulpride (2.0ng/mL) and 
Amisulpride-d5 (200 ng/mL) are shown in Fig. 3b. 
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Fig. 3a.   MRM Chromatogram of Blank Human Plasma 
   
Amisulpride  Amisulpride-d5 
Fig. 3b.  Chromatogram of LOQ 592  R. Mogili et al.:   
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Linearity, Precision and Accuracy 
Calibration curves were plotted as the peak area ratio (Amisulpride / Amisulpride-d5) 
versus concentration of Amisulpride. Calibration was found to be linear over the 
concentration range of 2.0–2500.0 ng/mL for Amisulpride (Fig.  4). The CV% for 
Amisulpride was less than 3.9%. The accuracy ranged from 96.5 to 101.5% for 
Amisulpride. The determination coefficient (r
2) for Amisulpride was greater than 0.9998 for 
all curves (Table 1). Precision and accuracy for this method were controlled by calculating 
the intra- and inter-batch variations of QC samples in six replicates at three concentrations 
(6.0, 750.0 and 1750.0 ng/mL) for Amisulpride as shown in Table 2. The intra-batch CV% 
was less than 1.7 % for Amisulpride. These results indicate the adequate reliability and 
reproducibility of this method within the analytical range. This method demonstrated intra- 
and inter-day Accuracy within 96.0% to 101.5% for Amisulpride. 
 
Fig. 4.  Calibration curve 
Tab. 1.  Calibration curves from one batch of the validation section 
Spiked plasma 
concentration 
(ng/mL) 
Concentration 
measured(mean) 
(ng/mL)±SD 
CV (%) 
(n = 5) 
Accuracy 
% 
2.00  2.03 ± 0.03  1.5  101.5 
4.00  3.86 ± 0.15  3.9  96.5 
10.00  10.09± 0.13  1.3  99.1 
25.00  25.07 ± 0.68  2.7  99.7 
250.00  252.26 ± 5.04  2.0  99.1 
500.00  499.91 ± 6.48  1.3  100.0 
1000.00  989.99 ± 18.14  1.8  99.0 
1500.00  1514.93 ± 46.87  3.1  101.0 
2000.00  2026.48 ± 43.40  2.1  101.3 
2500.00  2464.29 ± 90.38  3.7  98.6   Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem …  593 
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Tab. 2.  Precision and accuracy (analysis with spiking plasma samples at four different 
concentrations) 
Spiked 
plasma 
concen-
tration 
(ng/mL) 
Within-run  Between-run 
Concentration 
measured 
(n=6) (ng/mL) 
(mean ± S.D) 
R.S.D.
a 
(%) 
Accuracy  
% 
Concentration 
measured 
(n=30) (ng/mL) 
(mean±S.D.) 
R.S.D.
a 
(%) 
Accuracy  
% 
2.00  1.99 ± 0.20  1.6  99.50  1.97 ± 0.18  1.5  98.42 
6.00  5.90 ± 0.10  1.7  98.3  5.76 ± 0.15  2.6  96.0 
750.00  761.14 ± 6.58  0.9  101.5  757.34 ± 11.57  1.5  101.0 
1750.00  1746.15 ± 20.44  1.2  99.8  1763.73 ± 49.24  2.8  100.8 
a 
Standard deviation
Mean concentration measured
×100 
 
Recovery 
The recovery following the sample preparation using liquid-liquid extraction method with 
diethyl ether was calculated by comparing the peak areas of drug in plasma samples with 
the peak area ratios of solvent samples and was estimated at control levels of drug. The 
recovery of Amisulpride (at concentrations 6.0, 750.0 and 1750.0 ng/mL) was found to be 
74.00, 73.97 and 75.93%. The overall average recovery of Amisulpride was found to be 
74.63%. The overall average recovery of Amisulpride-d5 was found to be 65.07 %. 
Limits of Quantification (LOQ) and Detection (LOD) 
The LOQ found for this method is 2.0 ng/ mL with signal-to-noise (S/N) of 30.6. Limit of 
detection (LOD) was estimated by measuring S/N values obtained in human plasma 
spiked at 50.0 pg/ mL level and extrapolating the corresponding values to S/N=12.18. The 
LOD value was 0.25 pg for Amisulpride. 
Matrix effect 
The CV % of ion suppression/enhancement in the signal was found to be 1.2% at MQC 
level for Amisulpride, indicating that the matrix effect on the ionization of the analyte is 
within the acceptable range under these conditions. 
Stability (Freeze - thaw, Auto sampler, Bench top, Long term). 
Quantification of the Amisulpride in plasma subjected to 3 freeze-thaw (−30°C to room 
temperature) cycles showed the stability of the analyte. The concentrations ranged from 
99.0 to 104.0% for Amisulpride of the theoretical values. No significant degradation of the 
Amisulpride was observed even after a 99 h storage period in the auto sampler tray and 
the final concentrations of Amisulpride was between 104.83 to 103.94% of the theoretical 
values. The room temperature stability of Amisulpride in QC samples after 25 h was also 
evaluated. The concentrations ranged from 94.67 to 102.9% for Amisulpride of the 
theoretical values. In addition, the long-term stability of Amisulpride in QC samples after 55 
days of storage at −30°C was also evaluated. The concentrations ranged from 93.16 to 
103.3% for amisulpride of the theoretical values. These results confirmed the stability of 
Amisulpride in human plasma for at least 55 days at −30°C (Table 3). 594  R. Mogili et al.:   
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Tab. 3.  Stability of the samples 
Spiked plasma  
concentration 
(ng/mL) 
Room temperature/ 
Benchtop stability 
Autosampler 
stability 
25.0 h  99.0 h 
Concentration 
measured 
(n=6) (ng/mL) 
(mean±S.D) 
(n=6) 
CV(%) 
Concentration 
measured 
(n=6) 
(ng/mL) 
(mean±S.D) 
(n=6) 
CV(%) 
6.00  5.68 ± 0.13  2.4  6.29 ± 0.14  2.2 
1750.00  1801.90 ± 22.31  1.2  1818.89 ± 24.78  1.4 
Spiked plasma  
concentration 
(ng/mL) 
Long term 
stability 
Freeze and thaw 
stability 
55 days  Cycle 3 (48 h) 
Concentration 
measured 
(n=6) 
(ng/mL) 
(mean±S.D) 
(n=6) 
CV(%) 
Concentration 
measured 
(n=6) 
(ng/mL) 
(mean±S.D) 
(n=6) 
CV(%) 
6.00  5.59 ± 0.04  0.7  5.94 ± 0.4  7.3 
1750.00  1807.13 ± 21.13  1.2  1820.14 ± 25.99  1.4 
 
Application to pharmacokinetic study 
The above-validated method was used in the determination of AM in plasma samples for 
establishing the bioequivalence of a single 50-mg dose (one 50 mg tablet) in 10 healthy 
human volunteers. Typical plasma concentration versus time profiles are shown in Fig. 5. 
All the plasma concentrations of AM were in the standard curve  region and remained 
above the 2.00 ng mL
−1  LOQ for the entire sampling period. The pharmacokinetic 
parameters and 90%CI are shown in Table 4 and 5. Therefore, it can be concluded that 
the  two Amisulpride formulations (reference and test) analyzed were bioequivalent 
according to regulatory requirements [39–41].  
Tab. 4.   Mean pharmacokinetic parameters of Amisulpride in 10 healthy volunteers after 
oral administration of 50 mg test and reference products. 
Amisulpride  Pharmacokinetic Parameter 
Cmax  
(ng/ mL) 
Tmax  
(hr) 
AUC0-t 
(ng. hr/mL) 
AUC0-∞ 
(ng. hr/mL) 
Test  947.9  3  10710.8  10864.3 
Reference  1093.4  3  11660.4  11817.7 
AUC0-∞…area under the curve extrapolated to infinity; AUC0-t…area under the 
curve up to the last sampling time; Cmax…the maximum plasma concentration; 
Tmax…the time to reach peak concentration. 
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Fig. 5.   Mean plasma concentrations of test vs. reference after a 50 mg dose (one 50 
mg tablet) in 10 healthy volunteers 
Tab. 5.  Test/Reference values for log-transformed pharmacokinetic parameters of 
Amisulpride after oral administration of 50 mg of test and reference products in 
10 healthy male volunteers 
  Pharmacokinetic Parameter 
Cmax  
(ng /mL) 
AUC0-t 
(ng. hr/mL) 
AUC0-∞  
(ng. hr/mL) 
Test/ Reference  86.7  91.8  91.9 
 
Conclusion 
The method described here is fast, rugged and reproducible, and sensitive. Each sample 
requires less than 2.5 min of analysis time for determination of Amisulpride in human 
plasma by LC-MS/MS. The deuterated compound Amisulpride-d5 was used as an internal 
standard. We have developed and validated the method as per the FDA guidelines over a 
concentration range of 2.0–2500.0 ng/mL for Amisulpride using a 100µL plasma sample 
followed by a simple liquid-liquid extraction technique for extraction of the drug and internal 
standard. This method could be useful for application in clinical pharmacokinetic studies. 
Acknowledgment 
The authors wish to thank the support received from IICT (Indian Institute of Chemical 
Technology) Hyderabad, India, for providing literature survey, Jawaharlal Nehru 
Technological University, Anantapur, India and APL Research Centre, Hyderabad, India.  596  R. Mogili et al.:   
Sci Pharm. 2011; 79: 583–599 
Authors’ Statements 
Competing Interests 
The authors declare no conflict of interest. 
Informed Consent, Ethical Approvals 
The institutional and (inter)national ethical guides for experiments on human subjects were 
followed and informed consent was obtained. See the part ‘method development and 
validation’ for details. 
References 
[1]  Coukell AJ, Spencer CM, Benfield P. 
Amisulpride: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic 
Efficacy in the Management of Schizophrenia. 
CNS Drugs. 1996; 6: 237–243.  
doi:10.2165/00023210-199606030-00006 
[2]  Costa e Silva JA. 
The public health impact of anxiety disorders: a WHO perspective.  
Acta Psychiatr Scand Suppl. 1998; 393: 2–5. 
PMid:9777040 
[3]  Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Mazière B, Paillère-Martinot ML. 
In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia. 
J Clin Psychopharmacol. 2001; 21: 207–214. 
PMid:11270918 
[4]  Curran MP, Perry CM. 
Spotlight on Amisulpride in Schizophrenia.  
CNS Drugs. 2002; 16: 207–211.  
doi:10.2165/00023210-200216030-00007 
[5]  Geddes J, Freemantle N, Harrison P, Bebbington P.  
Atypical antipsychotics in the treatment of Schizophrenia: systematic overview and meta-regression 
analysis.  
BMJ. 2000; 321: 1371–1376.  
doi:10.1136/bmj.321.7273.1371 
[6]  Stanniland C, Taylor D.  
Tolerability of Atypical Antipsychotics.  
Drug Safety. 2000; 22: 195–214.  
doi:10.2165/00002018-200022030-00004 
[7]  Isbister GK, Balit CR, Macleod D, Duffull SB. 
Amisulpride Overdose Is Frequently Associated With QT Prolongation and Torsades de Pointes. 
J Clin Psychopharmacol. 2010; 30: 391–395. 
doi:10.1097/JCP.0b013e3181e5c14c 
[8]  Noble S, Benfield P. 
Amisulpride: A Review of its Clinical Potential in Dysthymia.  
CNS Drugs. 1999; 12: 471–483. 
doi:10.2165/00023210-199912060-00005 
[9]  Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk I, Ahtoy P, Chretien P, Rosenzweig P, 
Nasr A, Piette F. 
Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.  
Eur J Clin Pharmacol. 1998; 54: 405–409. 
doi:10.1007/s002280050483   Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem …  597 
Sci Pharm. 2011; 79: 583–599 
[10]  Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. 
A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy 
volunteers.  
Hum Psychopharmacol. 2002; 17: 1–13. 
doi:10.1002/hup.320 
[11]  Canal M, MacMahon M, Kwan J, Dubruc C.  
Amisulpride: kinetics in patients with renal failure. 
Eur Neuropsychopharmacol. 2000; 10 (Suppl 3): 330. 
doi:10.1016/S0924-977X(00)80404-6 
[12]  Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K, Ajjala D, Suraneni R, Mukkanti K.  
Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with 
LLOQ of 100 pg/mL using 100 microL of plasma. 
Biomed Chromatogr. 2008; 22: 1424–1433. 
doi:10.1002/bmc.1076 
[13]  Kratzsch C, Peters FT, Kraemer T, Weber AA, Maurer HH. 
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three 
of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure 
chemical ionization.  
J Mass Spectrom. 2003; 38: 283–295. 
doi:10.1002/jms.440 
[14]  Gschwend MH, Arnold P, Ring J, Martin W. 
Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-
tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring.  
J Chromatogr B Analyt Technol Biomed Life Sci. 2006: 831:132–139.  
doi:10.1016/j.jchromb.2005.11.042 
[15]  Kirchherr H, Kühn-Velten WN. 
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC 
tandem mass spectrometry: a multi-level, singlesample approach.  
J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 843: 100–113.  
doi:10.1016/j.jchromb.2006.05.031 
[16]  Couchman L, Morgan PE, Flanagan RJ. 
Basic drug analysis by strong cation-exchange liquid chromatography-tandem mass spectrometry 
simultaneous analysis of amisulpride and metamfetamine and amphetamine in serum/plasma.  
Biomed Chromatogr. 2011: 25: 867–872.  
doi:10.1002/bmc.1530 
[17]  Zou S, Wen Y, Lin Q. 
Determination of amisulpride in plasma by LC/MS/MS. 
Zhongguo Xiandai Yingyong Yaoxue. 2009; 26: 483–486. 
[18]  Frahnert C, Rao ML, Grasmader K. 
Analysis of eighteen antidepressants, four atypical anti psychotics and active metabolites in serum by 
liquid chromatography: a simple tool for therapeutic drug monitoring. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 794: 35–47. 
doi:10.1016/S1570-0232(03)00393-3 
[19]  Chiba R, Ogasawara A, Kubo T, Yamazaki H, Umino M, Ishizuka Y. 
Direct determination of benzamides in serum by column-switching highperformance liquid 
chromatography. 
Anal Sci. 2003; 19: 785–789. 
doi:10.2116/analsci.19.785 
[20]  Pehourcq F, Ouariki S, Begaud B. 
Rapid high-performance liquid chromatographic measurement of amisulpride in human plasma: 
application to manage acute intoxication. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 789: 101–105. 
doi:10.1016/S1570-0232(03)00045-X 598  R. Mogili et al.:   
Sci Pharm. 2011; 79: 583–599 
[21]  Sachse J, Hartter S, Weigmann H, Hiemke C. 
Automated determination of amisulpride by liquid chromatography with column switching and 
spectrophotometric detection. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 784: 405–410. 
doi:10.1016/S1570-0232(02)00808-5 
[22]  Jitsufuchi N, Kudo K, Tokunaga H, Imamura T. 
Selective determination of sultopride in human plasma using highperformance liquid chromatography 
with ultraviolet detection and particle beam mass spectrometry.  
J Chromatogr B Biomed Sci Appl. 1997; 690: 153–159. 
doi:10.1016/S0378-4347(96)00423-9 
[23]  Malavasi B, Locatelli M, Ripamonti M, Ascalone V. 
Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid-liquid 
extraction or solid-phase extraction in combination with highperformance liquid chromatography and 
fluorescence detection. application to pharmacokinetics. 
J Chromatogr B Biomed Appl. 1996; 676: 107–115. 
doi:10.1016/0378-4347(95)00420-3 
[24]  Kamizono A, Inotsume N, Fukushima S, Nakano M. 
Disposition of enantiomers of sultopride in a human. rats and rabbits.  
Biol Pharm Bull. 1993; 16: 1121–1123. 
PMid:7906175 
[25]  Moulin A, Truffer D, Rauch-Desanti C, Istin M, Grognet JM, Dufour A. 
Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma.  
Eur J Drug Metab Pharmacokinet. 1991; 3: 507–512. 
PMid:1820931 
[26]  de Jong AP, Wittebrood AJ, du Chatinier WM, Bron J. 
Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using 
solid-phase extraction.  
J Chromatogr. 1987; 419: 233–242. 
PMid:3667781 
[27]  Nishihara K, Kohda Y, Tamura Z. 
Determination of sultopride in serum and saliva by high-performance liquid chromatography.  
Chem Pharm Bull (Tokyo). 1983: 31: 4144–4146. 
PMid:6671246 
[28]  Bohbot M, Doare L, Diquet B. 
Determination of a new benzamide, amisulpride, in human plasma by reversed-phase ion-pair high-
performance liquid chromatography.  
J Chromatogr. 1987; 416: 414–419. 
PMid:2886513 
[29]  Bressolle F, Bres J. 
Determination of sulpiride and sultopride by high-performance liquidchromatography for 
pharmacokinetic studies.  
J Chromatogr. 1985; 341: 391–399. 
PMid:4030988 
[30]  Mokrim R, Brunet C, Cazin M, Gressier B, Luyckx M, Dine T, Robert H, Cazin JC. 
Amisulpride evaluation bv radioreceptor assav comparison with HPLC procedure after single 
administration in the rabbit. 
Methods Find Exp Clin Pharmacol. 1993; 15: 41–47. 
PMid:8097546   Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem …  599 
Sci Pharm. 2011; 79: 583–599 
[31]  Ascalone V, Ripamonti M, Malavasi B. 
Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine 
by automated solid-phase extraction and liquid chromatography on a chiral column. application to 
pharmacokinetics. 
J Chromatogr B Biomed Appl. 1996: 676: 95–105. 
doi:10.1016/0378-4347(95)00418-1 
[32]  Das A, Bhaumik U, Chakrabarty US, Sarkar AK, Ghosh A, Bose A, Chatterjee B, Pal TK. 
Comparative bioavailability study of amisulpride tablets in healthy Indian volunteers.  
Arzneimittelforschung. 2009; 59: 166–170. 
PMid:19517892 
[33]  Kudris IV, Skakun NN, Orlova IN, Libina VV, Kulikov AU. 
Analysis of Amisulpride in Human Plasma by SPE and LC with Fluorescence Detection.  
Chromatographia. 2011; 73: 67–74.  
doi:10.1007/s10337-010-1832-2 
[34]  Shams M, Hiemke C, Härtter S. 
Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in 
human serum. 
Ther Drug Monit. 2004; 26: 78–84. 
doi:10.1097/00007691-200402000-00015 
[35]  Someya T, Shimoda K, Muratake T, Nakajima E, Shirai A, Funaoka H, Yashiki T, Ishii H, Sunahara N, 
Takahashi S. 
Establishment of enzyme immunoassay for measuring serum sultopride levels. 
Ther Drug Monit. 2001; 23: 277–281. 
doi:10.1097/00007691-200106000-00016 
[36]  Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. 
Plasma concentrations of antipsychotic drugs in psychiatric inpatients. 
Nihon Hoigaku Zasshi. 1997; 51: 417–422. 
PMid:9545754 
[37]  Skibinski R, Komsta L, Hopkala H, Suchodolska I. 
Comparative validation of amisulpride determination in pharmaceuticals by several chromatographic, 
electrophoretic and spectrophotometric methods.  
Anal Chim Acta. 2007; 590: 195–202.  
doi:10.1016/j.aca.2007.03.038 
[38]  Süzen S, Demírcígíl BT, Buyukbingol E, Özkan SA. 
Electroanalytical evaluation and determination of 5-(3′-indolyl)-2-thiohydantoin derivatives by 
voltametric studies: possible relevance to in vitro metabolism. 
New J Chem. 2003; 27: 1007–1011. 
doi:10.1039/b300160c 
[39]  Guidance for industry: bioanalytical method validation. 
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research(CDER), Center for Biologics Evaluation and Research (CBER), May 2001. 
[40]  Guidance for industry: Food-effect bio availability and Fed Bio equivalence studies. 
U.S.Department of Health and Human services Food and Drug Administration Centre for Drug 
Evaluation and research (CDER) December 2002. 
[41]  Guidance for industry Bio availability and Fed Bio equivalence Studies for Orally Administered Drug 
Products-General considerations. 
U.S.Department of Health and Human services Food and Drug Administration Centre for Drug 
Evaluation and research (CDER) March 2003. 
 